25 results about "Immune Factors" patented technology

The invention belongs to the technical field of bioengineering, and particularly relates to leuconostoc mesenteroides subsp. Mesenteroides FTCM002 and application thereof in preparation of dendrobium officinale leavening with the effects of reducing blood sugar, nourishing the stomach and resisting inflammation. Dendrobium officinale is subjected to enzymolysis and inoculated with the strain for fermentation, and the obtained fermented dendrobium officinale has the effect of inhibiting alpha-glucosidase; the gastric mucosal injury can be relieved, the expression of VEGF, IL-6, IL-8 and TNF-alpha in the gastric mucosal injury is reduced, and the effect of nourishing the stomach is achieved; the cell phagocytic rate can be increased, the NO concentration and the content of immune factors IL-6 and TNF-alpha can be increased, and the effect of enhancing the immunity is achieved; the expression quantity of IL-6, IL-1beta and TNF-alpha in inflammatory cells can be reduced, and the anti-inflammatory effect is achieved.

The application provides a construction method of a humanized keloid mouse model, comprising the following steps: BAC plasmid construction and preparation; superovulation of experimental mice and collection of zygotes; pronuclear microinjection of zygotes; post-injection embryo transplantation; genotype identification; breeding and genetic analysis; and verification of construction results of the humanized immune system by immunohistochemistry and immunofluorescence. In the application, peripheral blood mononuclear cells treated by sCD27 and skin around keloids (homologous cells and tissues) are transplanted into NSG-MHC-DKO immune-deficient mice with overexpression of CD70 genes, so that HLA rejection of different homologous immune cells and tissues can be avoided, the internal microenvironment of keloids and the interaction between the internal microenvironment and the immune system can be restored to the maximum extent, and the influence of immune factors on the occurrence and development of keloids can be realized in vitro. The application first discovers and verifies that the activation of the CD27-CD70 axis can promote the occurrence and development of keloids, and provides a suitable animal model for the research and development of anti-keloid drugs, especially immunotherapy.

The invention provides application of M1 protein related substances in preparation of medicines for treating diseases caused by avian influenza viruses. The application is any one of the following applications: application of Y1 in preparation of medicines for preventing and / or treating diseases caused by avian influenza viruses or avian influenza virus infection; the Y2 is applied to preparation of an avian influenza virus inhibitor; the invention discloses application of Y3 in inhibition of avian influenza virus replication. After a mouse is immunized by the M1 recombinant protein, immune factors related to T cells are increased, secretion of proinflammatory factors is reduced, preparation is made for protecting a body from virus attack, and the M1 recombinant protein is also an expression for laterally improving the immunity of a host. The M1 protein has a good immune effect as an immunogen. The invention has application value in treatment of avian influenza virus and similar viruses.

The present application relates to the field of microbial technology, and particularly relates to bifidobacterium BB36 with improved antigen presentation ability and enriched calcium, iron and selenium, probiotics and application thereof. Bifidobacterium bifidum The present application provides bifidobacterium BB36 with activated macrophages, up-regulated immune factor expression level, and activated dendritic cells, enhanced antigen presentation ability in immune process, and enriched calcium, iron and selenium, and can be used as a biological carrier of mineral elements, in addition, can inhibit the growth of escherichia coli and staphylococcus aureus, and protect intestinal health of the body.

This application belongs to the field of microbial technology, and mainly relates to a strain of *Pediococcus lactis* BPA03 and its applications. *Pediococcus lactis* BPA03 is classified and named *Pediococcus lactis*. Pediococcus acidilactici This *Pediococcus lactis* strain BPA03 was deposited on September 28, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 36109. It inhibits skin melanin deposition and improves UV photoaging, suppresses the gene expression levels of immune factors such as IL-1β, IL-6, IL-8, and TNF-α, improves the activities of superoxide dismutase, catalase, and glutathione peroxidase, inhibits vinorelbine-induced neutropenia, and improves the inhibition of immune factor expression induced by vinorelbine, thus exhibiting comprehensive anti-aging effects.

The application discloses a quinazoline-4(3H)-ketone compound and a preparation method, a pharmaceutical composition and application thereof, the structure of the compound is as shown in the formula (I), and the compound comprises isomers, pharmaceutically acceptable salts or mixtures thereof. The compound and the pharmaceutical composition thereof have a high inhibitory effect on PARP7, the inhibitory activity reaches a nanomolar concentration level, can significantly promote the release of immune factors, are used for immunotherapy of tumors, and can exert good drug efficacy at a molecular level and a cell level. In addition, the preparation method of the compound is simple and easy to implement.

This invention belongs to the field of active ingredient extraction and purification technology, specifically a neutral polysaccharide ORP-0 from *Agaricus bisporus* and its applications. The preparation method of this invention includes the following steps: (1) pretreatment; (2) polysaccharide extraction; (3) impurity removal; and (4) separation and purification. This invention obtains a single neutral polysaccharide ORP-0 through defatting pretreatment, ultrasonic-assisted extraction, multiple impurity removal processes, and separation and purification using a DEAE-52 cellulose chromatography column. The method of this invention is simple to operate, has mild reaction conditions, and a complete impurity removal process. The obtained neutral polysaccharide has high purity, with a total sugar content of 92.09%. Furthermore, the obtained neutral polysaccharide ORP-0 enhances the activity of RAW 264.7 macrophages, increases the release of immune factors, enhances the expression of phosphorylated proteins in the MAPK signaling pathway, and activates the body's immune response.

The invention discloses an application of a combination of a ficus pandurata aqueous extract and a PD-1 antibody in preparation of a medicine for preventing or treating colorectal cancer. The ficus pandurata water extract and the PD-1 antibody are creatively combined for use, and experimental results show that on one hand, the combination of the ficus pandurata water extract and the PD-1 antibody can synergistically inhibit tumor growth, improve the anti-tumor immune cell factor level and remarkably enhance the treatment effect on the colorectal cancer CRC; a new direction is provided for breaking through the clinical bottlenecks that the colorectal cancer CRC immunotherapy is low in response rate and limited in single-drug curative effect; on the other hand, the combination of the two drugs has no obvious toxic and side effects on heart, lung, liver and kidney, can reduce adverse effects on the spleen, has a potential protection effect on the important immune organ of the spleen, and is helpful to maintain the normal immune function of the organism.

The invention belongs to the technical field of detection, and particularly discloses a measurement uncertainty evaluation method for measuring immune factors in serum by an ELISA (enzyme-linked immuno sorbent assay) method. According to the method, ELISA detection is carried out on immune factors (such as IL-1beta) in serum of an experimental animal in contact with a medical instrument according to standards such as GB / T16886.20-2015, system analysis comprises nine types of uncertainty sources such as repeated detection, standard substance preparation and sample dilution, the standard uncertainty of each component is calculated through mathematical methods such as rectangular distribution and a least square method, and the standard uncertainty of each component is calculated according to the standard uncertainty. And synthesizing the standard uncertainty and calculating the expansion uncertainty, and finally outputting a standard detection result. The method comprehensively covers the uncertainty source, is rigorous in computational logic and clear in key quality control factors, provides a scientific and complete uncertainty evaluation scheme for medical instrument immunogenicity evaluation and immune factor determination in other experimental scenes, is beneficial to laboratory quality control and detection result optimization, and has wide practicability.

The application belongs to the field of marine biotechnology, and particularly relates to natural polysaccharide-quaternized chitosan nanoparticles with immune stimulation and preparation and application thereof. The nanoparticles formed by natural polysaccharide with negative charge and quaternized chitosan with positive charge are obtained by polyelectrolyte complexation, the particle size is 316.4 nm, and the potential is 31.1 mV; the quaternized chitosan with positive charge and the natural polysaccharide with negative charge are mixed in a mass ratio of 6.25-10:1-4. After immunization of mice, the secretion amount of immunoglobulin IgG and immune factors in the mice is determined, which shows that the nanoparticles have good immune activity, thereby playing an effect in vaccine adjuvant. The application provides a method and guidance for the research on natural polysaccharide and chitosan derivatives as immune adjuvants in recent years.

The invention provides a combined vaccine based on Th1 / Th2 immune dynamic equilibrium as well as a preparation method and application of the combined vaccine. Subcutaneous delivery of interleukin 12 (IL12) and antigen (such as ovalbumin OVA) mRNA is adopted in the early stage of tumor occurrence, so that specific antigen recognition and T cell immune response of an organism are activated; when immune response enters a function decline stage, the tumor microenvironment is regulated through intratumor delivery of interleukin 4 (IL4) mRNA, the metabolic activity of T cells is maintained, and the depletion of the T cells is delayed. Through space (subcutaneous / intra-tumor) and time (early stage / middle stage) separated delivery of different immune factors, 'start-steady state maintenance 'type immune stylization regulation and control are realized, antigen-specific CTL reaction and persistent anti-tumor effect are remarkably enhanced, and the problem of immune bias caused by independent use of the antigen-specific CTL reaction and the persistent anti-tumor effect is solved.

The invention belongs to the technical field of environmental toxicology and biological detection, and particularly relates to a pollutant immunotoxicity comprehensive evaluation method based on a zebra fish model. The invention aims to establish a multi-level and multi-index fused immunotoxicity evaluation system, and by combining indexes such as immune cell quantity, humoral immune factors and immune-related gene expression and constructing a comprehensive immunotoxicity index (ITI), quantitative and comprehensive judgment of pollutant immune injury is realized. Therefore, a scientific basis is provided for rapid identification and risk evaluation of immunotoxicity of environmental pollutants.

This invention discloses a biological agent suitable for squab growth, its preparation method, and its application, belonging to the field of feed technology. It comprises the following components by weight: 8-40 parts of microbial agent, 1-10 parts of additive, 1-10 parts of antioxidant, 0.5-5 parts of peptidoglycan, and 40-60 parts of montmorillonite. The microbial agent includes *Bifidobacterium animalis*, *Lactobacillus acidophilus*, *Lactobacillus paracasei*, and *Lactobacillus reuteri*. The additive includes at least one of yeast β-glucan and astragalus polysaccharide. The biological agent for squab growth of this application uses montmorillonite as a base material. Under the combined action of the microbial agent, additive, antioxidant, and peptidoglycan, it can regulate the intestinal health of breeding pigeons, improve their immunity, and increase immune factors in pigeon milk. This can improve the growth performance of squabs, reduce the culling rate of both breeding and squabs, thereby increasing economic benefits and showing broad application prospects.

The invention discloses a neural immune factor real-time monitoring device, and belongs to the technical field of medical detection. The neural immune factor real-time monitoring device comprises a non-invasive sampling module, a sensing detection module, an intelligent analysis module and a communication feedback module. The invention solves the problem that the existing detection method depends on invasive sampling and cannot realize continuous, stable and synchronous monitoring of multi-target neural immune factors, and realizes non-invasive and automatic sample collection and pretreatment by integrating the hollow microneedle array and the micro-fluidic chip. The sensor array with the automatic calibration unit is used for multi-target synchronous detection, long-term accuracy and anti-interference capability of multi-target synchronous detection are ensured, and in combination with a built-in adaptive calibration algorithm and an intelligent analysis program, accuracy, stability and convenience of long-term monitoring are improved. Effective continuous data support can be provided for dynamic evaluation and early warning of neuroimmune related diseases.

The invention provides a 6-diazo-5-oxo-n-leucine prodrug and a preparation method and application thereof.According to the 6-diazo-5-oxo-n-leucine prodrug and a compound, a glutamine metabolism inhibitor JHU083 and an STING pathway agonist MSA-2 are connected through a cleavable amido bond, two action mechanisms are fused, the activity of the 6-diazo-5-oxo-n-leucine prodrug is improved, the activity of the 6-diazo-5-oxo-n-leucine prodrug is improved, and the activity of the 6-diazo-5-oxo-n-leucine prodrug is improved. On one hand, the metabolic advantage of tumor cells is limited, and the immunosuppressed tumor microenvironment is reversed; the STING pathway of dendritic cells is directly activated, immune factors such as type I interferon and tumor necrosis factor TNF-alpha are induced to release, and immune activation is synergistically enhanced; the dendritic cell function is improved, the antigen presentation capability is enhanced, the co-stimulatory molecule expression level of DC can be remarkably improved, the antigen presentation capability of the DC can be enhanced, the activation efficiency of T cells is improved, and the anti-tumor immune effect is enhanced; and the compound has good chemical stability and drug development potential, is suitable for further pharmacological research and preclinical development, and has good synthesizability and pharmaceutical properties.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum BB36 capable of improving antigen presentation capacity and enriching calcium, iron and selenium, a metagen and application of the bifidobacterium bifidum BB36. The bifidobacterium bifidum BB36 disclosed by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on February 2, 2026, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No.37593. The invention further discloses a preparation method of the bifidobacterium bifidum BB36. The bifidobacterium bifidum BB36 provided by the invention has the effects of activating macrophages, up-regulating the expression level of immune factors, directly activating dendritic cells and enhancing the antigen presentation capacity in the immune process, has the capacity of enriching calcium, iron and selenium, and can be used as a biological carrier of mineral elements; the growth of escherichia coli and staphylococcus aureus can be inhibited, and the intestinal health of a body is protected.

The invention discloses application of long-chain non-coding RNA (LncRNA) XR002626937.1 in regulation and control of replication of canine coronavirus (CCoV), and belongs to the technical field of biological medicine. The nucleotide sequence of the LncRNA XR002626937.1 is as shown in SEQ ID No.1, is mainly positioned in a cell nucleus, is remarkably up-regulated in time and dose dependence after MDCK cells are infected by CCoV, and is positively correlated with virus load. Functional experiments prove that overexpression of the LncRNA can significantly promote CCoV replication, and knock-down of the expression of the LncRNA can effectively inhibit virus proliferation; the action mechanism comprises the steps of inhibiting activation of a p53 signal channel and downstream target genes p21 and Bax, repressing apoptosis of infected cells, antagonizing expression of natural immune factors such as RIG-I, MAVS, ISG15 and the like, promoting virus immune escape, and being capable of serving as competitive endogenous RNA to adsorb miR-10926-z to regulate and control the downstream signal channel. The key function of the LncRNA XR002626937.1 in CCoV infection is defined for the first time, a new target spot and a theoretical basis are provided for developing the anti-CCoV medicine targeting the LncRNA, and the application prospect is wide.

According to the goat milk powder capable of nourishing the stomach and soothing the nerves and the preparation method, various nutritional ingredients including high-quality raw goat milk, rich vitamins and mineral substances, isomaltooligosacharide, inulin and xylooligosaccharide are scientifically proportioned, so that comprehensive and balanced nutrition is provided, and the goat milk powder is easy to digest and absorb, is particularly suitable for people needing to nourish the stomach and soothe the nerves, and has the effects of nourishing the stomach and soothing the nerves. In addition, the added triple compound probiotic powder is beneficial to regulating intestinal flora, promoting gastrointestinal tract peristalsis, relieving constipation and reducing intestinal problems, the bovine colostrum powder is rich in immune factors, sheep spleen peptide has the effects of tonifying spleen and qi, nourishing blood and tranquilizing, the combination of the bovine colostrum powder and the sheep spleen peptide can significantly improve immunity, and meanwhile, the addition of the hericium erinaceus powder and the Chinese yam powder is beneficial to tranquilizing and stabilizing mind. The milk powder can improve the sleep quality, is especially suitable for people with large pressure and poor sleep quality, and in addition, by adopting homogenization and spray drying technologies, milk powder particles are fine and uniform and are easy to dissolve, digest and absorb.

Methods, systems, and computer-implemented tools are provided for early prediction of preeclampsia from cervicovaginal samples as early as the first trimester. A method includes quantifying local immune factors (for example, comprising least one of Flt-3L, EOF, and IL- IRA) and determining vaginal microbiome features (including taxa such as a Prevotella species, a Bifidobacterium species, and a Gardnerella species), optionally together with maternal characteristics such as BMI, blood pressure, or medical history, and generating a numerical risk score using a trained model. In embodiments, reduced local concentrations of immune factors and BMI-conditioned microbial patterns (e.g., increased P. timonensis or reduced Bifidobacterium abundance) are associated with elevated risk, enabling risk assessment ~6 months prior to conventional clinical diagnosis. The disclosure further provides a system and kit to implement the assays and analytics, and non-transitory computer-readable media storing instructions to compute the risk score and support early clinical management.

The invention belongs to the technical field of medicines, and particularly relates to application of orientin in preparation of a medicine for treating breast cancer. An MMTV-PyMT breast cancer transgenic mouse is adopted, it is found that the tumor weight inhibition rate of 31.2% is achieved when the PD-L1 monoclonal antibody is independently used, the inhibition rate of orientin single drug treatment is 25.6%, after the PD-L1 monoclonal antibody and the orientin single drug are jointly used, tumor growth can be remarkably inhibited, the tumor inhibition rate reaches 70.0%, and the combined treatment effect is remarkably superior to simple superposition of the drug effects of all the single drugs. In addition, the combined treatment can also effectively promote the infiltration of CD4 + and CD8 + T cells in tumor tissues, and improve the expression level of key anti-tumor immune factors such as granzyme B (GZMB) and interferon-gamma (IFN-gamma).

The application belongs to the technical field of biological feed, and discloses a composition for improving immunity of young pets and application thereof, wherein the composition comprises soybean peptides and beta-glucan, and the mass ratio of the soybean peptides to the beta-glucan is 5:1-10:1. Experiments show that the composition can significantly improve the weight growth rate of young pets, improve the body condition and fecal state, increase the content of serum protein, immunoglobulin and various immune factors, increase the level of fecal secreted immunoglobulin A, and effectively enhance the whole body immunity and intestinal mucosal immunity of young pets. The composition is safe and efficient, low in cost, and has strong compatibility with pet daily food, and is suitable for preparing pet food, animal feed and related additives, and can be widely used for immune enhancement and health care of various young pets such as cats and dogs, and solves the technical problems of single function, poor effect and high cost of existing products.

The invention discloses hippocampus glycoprotein with an immune regulation function as well as a preparation method and application of the hippocampus glycoprotein, and belongs to the technical field of biological medicines. The hippocampus glycoprotein is prepared through optimization of a membrane separation process, the hippocampus glycoprotein is an N-glycosylation and chondroitin sulfate co-modified composite glycoprotein, the protein totally contains 65 different types of N-carbohydrate chains, the ratio of sialylated N-carbohydrate chains exceeds 30%, and the carbohydrate chain structure types comprise H5N4S1, H5N4S2, H6N5S1, H6N5S2 and the like; meanwhile, rich glycosaminoglycans (GAGs) are combined on the hippocampus glycoprotein, chondroitin sulfate is taken as a main type, and the total sulfation degree is 0.4-0.6. The hippocampus glycoprotein can effectively activate macrophages and promote secretion of immune factors such as NO, TNF-alpha and IL-6, and has remarkable immunomodulatory activity. According to the hippocampus glycoprotein provided by the invention, the hippocampus glycoprotein co-modified by N-glycosylation and chondroitin sulfate is taken as an active ingredient, and is supplemented with an acceptable carrier to prepare a medicine or a health care product, so that a new direction is provided for later development and application of related functions for immunoregulation.

The application relates to the technical field of deep learning, and discloses a liver cancer immunotherapy effect prediction method and system.The method comprises the following steps: performing multiple immunofluorescence staining pretreatment on a clinical sample, collecting forward scattering data, side scattering data and multi-channel fluorescence data of single nucleus cells, obtaining a cell expression initial data matrix, performing standardization processing to obtain a multi-dimensional feature matrix of immune factor expression, performing Bayesian network analysis to calculate the conditional probability relationship and mutual information value between immune cell factors, constructing an immune factor correlation network, performing abnormality detection to obtain immune factor expression abnormality detection results, performing minimum tail boundary analysis on the immune factor expression abnormality detection results, solving an optimal risk boundary through a semi-definite programming model, and outputting immune factor abnormality quantitative evaluation data, so that quantitative risk evaluation of a prediction result and fine classification of the prediction result are realized.

The present application relates to the technical field of biomedical engineering, and particularly relates to an engineered probiotic with a surface modification protective shell, a preparation method and application thereof, the engineered probiotic with the surface modification protective shell comprises a protective shell and an engineered probiotic, the protective shell is coated on the engineered probiotic; the engineered probiotic is surface modified by an immune regulation factor, and the surface of the engineered probiotic after surface modification is loaded with metal ions; the engineered probiotic with the surface modification protective shell can regulate immune factors, can be targeted and colonized in the colon, promote the repair of the mucosal surface, has a good treatment effect on intestinal inflammation, and thus is expected to be applied to the preparation of intestinal inflammation drug preparations; the preparation method of the engineered probiotic is easy to obtain raw materials, simple to operate, and controllable in reaction conditions, and is conducive to large-scale production.